Boothbay Fund Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.3M Buy
+14,644
New +$2.2M 0.03% 665
2024
Q3
Sell
-153,043
Closed -$16.3M 1827
2024
Q2
$16.3M Sell
153,043
-122,931
-45% -$12.3M 0.39% 27
2024
Q1
$26.7M Buy
275,974
+87,279
+46% +$8.95M 0.51% 21
2023
Q4
$19.1M Buy
188,695
+61,115
+48% +$5.9M 0.49% 17
2023
Q3
$13M Buy
127,580
+78,017
+157% +$7.92M 0.31% 50
2023
Q2
$5M Buy
+49,563
New +$4.96M 0.11% 206
2021
Q3
Sell
-2,442
Closed -$223K 2099
2021
Q2
$223K Sell
2,442
-5,578
-70% -$497K 0.01% 1458
2021
Q1
$686K Sell
8,020
-16,017
-67% -$1.44M 0.03% 774
2020
Q4
$2.27M Sell
24,037
-4,637
-16% -$405K 0.08% 236
2020
Q3
$2.49M Buy
28,674
+20,352
+245% +$1.76M 0.15% 170
2020
Q2
$727K Buy
+8,322
New +$718K 0.05% 473
2020
Q1
Sell
-23,354
Closed -$2.21M 991
2019
Q4
$2.21M Buy
23,354
+15,296
+190% +$1.37M 0.19% 135
2019
Q3
$700K Buy
+8,058
New +$724K 0.06% 387

Other funds holding NVS

Boothbay Fund Management's NVS Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Novartis (NVS) in Q2 2026: 14,644 shares worth $2.3M. The stake represents 0.03% of the portfolio and ranks #665 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in NVS as recently as Q2 2024.

Boothbay Fund Management first reported a position in NVS in Q3 2019 and has held it in 13 quarters since. The position peaked at $26.7M in Q1 2024. 1,620 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Boothbay Fund Management held 14,644 shares of Novartis worth $2.3M as of Q2 2026.
  • Novartis was a new Boothbay Fund Management position in Q2 2026.
  • Novartis made up 0.03% of Boothbay Fund Management's portfolio in Q2 2026, its #665 holding.
  • Boothbay Fund Management first reported a position in Novartis in Q3 2019 and has held it in 13 quarters since.
  • Boothbay Fund Management's Novartis position peaked at $26.7M in Q1 2024.
  • 1,620 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.